Patents by Inventor Sandy A. Simon

Sandy A. Simon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD37 immunotherapeutics and uses thereof
    Patent number: 10307481
    Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
    Type: Grant
    Filed: July 25, 2006
    Date of Patent: June 4, 2019
    Assignee: Aptevo Research and Development LLC
    Inventors: Laura S. Grosmaire, Martha S. Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter A. Thompson, Sandy A. Simon, William Brady
  • CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
    Patent number: 9101609
    Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: August 11, 2015
    Assignee: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
    Inventors: Philip Tan, Sandy A Simon, Charles G Cerveny, Christy Anne Nilsson, William Brady, Jeffrey A Ledbetter, Martha S Hayden-Ledbetter, Peter A Thompson, Cecile Morales
  • CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF
    Publication number: 20140086903
    Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 27, 2014
    Inventors: Philip TAN, Charles G. Cerveny, Sandy A. Simon, Anne Nilsson, William Brady, Peter A. Thompson, Cecile Morales
  • CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF
    Publication number: 20090274692
    Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.
    Type: Application
    Filed: April 13, 2009
    Publication date: November 5, 2009
    Applicant: Trubion Pharmaceuticals, Inc.
    Inventors: Phillip Tan, Sandy A. Simon, Charles G. Cerveny, Christy Anne Nilsson, William Brady, Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter, Peter A. Thompson, Cecile Morales
  • B-CELL REDUCTION USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
    Publication number: 20090214539
    Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
    Type: Application
    Filed: May 7, 2009
    Publication date: August 27, 2009
    Applicant: Trubion Pharmaceuticals, Inc.
    Inventors: Laura S. Grosmaire, Martha S. Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter A. Thompson, Sandy A. Simon, William Brady
  • B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
    Publication number: 20080279850
    Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
    Type: Application
    Filed: April 11, 2008
    Publication date: November 13, 2008
    Applicant: TRUBION PHARMACEUTICALS, INC.
    Inventors: William Brady, Martha S. Hayden-Ledbetter, Jeffrey A. Ledbetter, Sandy A. Simon, Peter A. Thompson
  • B-cell reduction using CD37-specific and CD20-specific binding molecules
    Publication number: 20070059306
    Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
    Type: Application
    Filed: July 25, 2006
    Publication date: March 15, 2007
    Applicant: TRUBION PHARMACEUTICALS, INC.
    Inventors: Laura Grosmaire, Martha Hayden-Ledbetter, Jeffrey Ledbetter, Peter Thompson, Sandy Simon, William Brady